Form 10-K Mersana Therapeutics, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Mersana (MRSN) PT Lowered to $11 at Wedbush
March 12, 2019 7:19 AM EDTWedbush analyst David Nierengarten lowered the price target on Mersana (NASDAQ: MRSN) to $11.00 (from $15.00) while maintaining a Outperform rating.
Ph 1b dose escalation data from MRSNs XMT-1536 is expected in 2Q19MRSN set to unveil their next clinical candidate in H2:19... More